Post-marketing safety evaluation of the live-attenuated chikungunya vaccine (IXCHIQ)

20260 citationsJournal Articlehybrid Open Access

Authors

Gerard T. Vondeling · Valneva (Austria)

Julio Croda · Universidade Federal de Mato Grosso do Sul

Tomas Jelinek · Berlin-Brandenburger Centrum für Regenerative Therapien

George Kassianos · Wokingham Hospital

Herwig Kollaritsch · Medical University of Vienna

Liem Binh Luong Nguyen · Inserm

Guilherme S. Ribeiro

Abstract

Early post-marketing SAEs occurred mainly in older adults with multimorbidity, reflecting reactogenicity patterns expected with live-attenuated vaccines, while serious events were uncommon in adults <65 years relative to doses administered. Regulatory reviews concluded that IXCHIQ's overall benefit-risk balance remains favourable within authorised and nationally recommended populations, and product information was updated to reinforce warnings, precautions, and contraindications.

Topics & Keywords

Mosquito-borne diseases and control Viral Infections and Outbreaks Research Poxvirus research and outbreaks

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Vaccine

Volume 79, pp. 128491-128491

DOI: 10.1016/j.vaccine.2026.128491

Field-Weighted Citation Impact: 0.00